The Role of Presepsin in Patients with Acute Surgical Diseases

Miras Mugazov; Yermek Turgunov; Dinar Kaliyeva; Dmitriy Matyushko; Zhandos Koishibayev; Dinara Omertayeva; Aidyn Nurbekov; Leyla Koishibayeva; Asylkhan Alibekov

doi:10.3889/oamjms.2019.292

Authors

Miras Mugazov Department of Surgical Diseases, Non-commercial Joint-stock Company, Karaganda Medical University, Karaganda, Kazakhstan
Yermek Turgunov Department of Surgical Diseases, Non-commercial Joint-stock Company, Karaganda Medical University, Karaganda, Kazakhstan
Dinar Kaliyeva Department of Surgical Diseases, Non-commercial Joint-stock Company, Karaganda Medical University, Karaganda, Kazakhstan
Dmitriy Matyushko Department of Surgical Diseases, Non-commercial Joint-stock Company, Karaganda Medical University, Karaganda, Kazakhstan
Zhandos Koishibayev Department of Surgical Diseases, Non-commercial Joint-stock Company, Karaganda Medical University, Karaganda, Kazakhstan
Dinara Omertayeva Department of Biochemistry, Non-commercial Joint-stock Company, Karaganda Medical University, Karaganda, Kazakhstan
Aidyn Nurbekov Department of Surgical Diseases, Non-commercial Joint-stock Company, Karaganda Medical University, Karaganda, Kazakhstan
Leyla Koishibayeva Department of Surgical Diseases, Non-commercial Joint-stock Company, Karaganda Medical University, Karaganda, Kazakhstan
Asylkhan Alibekov Department of Biochemistry, Non-commercial Joint-stock Company, Karaganda Medical University, Karaganda, Kazakhstan

DOI:

https://doi.org/10.3889/oamjms.2019.292

Keywords:

Intra-abdominal hypertension, Compartment syndrome, Presepsin, sCD14, D-dimer

Abstract

AIM: The purpose of this study was to determine the level of significance of markers in the development of intra-abdominal hypertension in patients with acute surgical diseases of the abdominal cavity.

METHODS: The authors surveyed 100 patients who were monitored at the Regional Clinical Hospital, Karaganda. The criterion for inclusion in the study was the informed consent of patients to participate in the study, the presence of acute surgical pathology, and the monitoring of intra-abdominal pressure over time. The exclusion criteria for patients from the study is the presence of sub and decompensation of associated diseases: trauma (hematoma of the bladder), bladder tumour and impaired integrity of the pelvic ring. The design of the study was by the legislation of the Republic of Kazakhstan, international ethical norms and normative documents of research organizations, approved by the ethics committee of the Karaganda State Medical University.

RESULTS: According to the world scientific literature, there are 4 indicators that change their value in response to increases in pressure in the abdominal cavity: fibrinogen and prothrombin index (the main indicators of the coagulogram); marker of blood clots D-dimer; early marker of translocation of bacterial flora into the bloodstream sCD14 (presepsin).

CONCLUSION: The authors concluded that the obtained data indicate that an increase in intra-abdominal pressure in acute surgical diseases of the abdominal cavity causes hypercoagulation and an increase in presepsin. Monitoring IAP with simultaneous measurement of the level of presepsin significantly improves the stratification of critical patients in need of emergency surgery.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001; 29(7):1303-1310. https://doi.org/10.1097/00003246-200107000-00002 PMid:11445675

Moore LJ, Moore FA, Todd SR, et al. Sepsis in general surgery: the 2005-2007 national surgical quality improvement program perspective. Arch Surg. 2010; 145 (7): 695-700. https://doi.org/10.1001/archsurg.2010.107 PMid:20644134

Moore LJ, Moore FA. Early diagnosis and care for surgical sepsis. J Intensive Care Med. 2013; 28(2):107-117. https://doi.org/10.1177/0885066611408690 PMid:21747125

Sridharan P, Chamberlain RS. The efficacy of procalcitonin as a biomarker in the management of sepsis: slaying dragons or tilting at windmills?. Surgical infections. 2013; 14(6):489-511. https://doi.org/10.1089/sur.2012.028 PMid:24274059

Okamura I, Tomer R. Presepsin: a new biomarker for predicting and diagnosing sepsis. Laboratory. 2014; 1: 9-10.

Antal-SzalmÃ¡s P. Evaluation of CD14 in host defence. European journal of clinical investigation. 2000; 30(2):167-79. https://doi.org/10.1046/j.1365-2362.2000.00610.x PMid:10651843

Scherberich JE, Nockher WA. CD 14++ monocytes, CD14+/CD16+ subset and soluble CD14 as biological markers of inflammatory systemic diseases and monitoring immuno-suppressive therapy. Clinical chemistry and laboratory medicine. 1999; 37(3):209-13. https://doi.org/10.1515/CCLM.1999.039

Sellati TJ, Bouis DA, Kitchens RL, Darveau RP, Pugin J, Ulevitch RJ, Gangloff SC, Goyert SM, Norgard MV, Radolf JD. Treponema pallidum and Borrelia burgdorferi lipoproteins and synthetic lipopeptides activate monocytic cells via a CD14-dependent pathway distinct from that used by lipopolysaccharide. The journal of Immunology. 1998; 160(11):5455-64.

Dziarski R, Tapping RI, Tobias PS. Binding of bacterial peptidoglycan to CD14. Journal of Biological Chemistry. 1998; 273(15):8680-90. https://doi.org/10.1074/jbc.273.15.8680 PMid:9535844

Klein BS. Role of Blastomycesdermatidis in the pathogenesis and immunobiology of blastomycosis. Semin Respir Infect. 1997; 12:198-205.

Antal-SzalmaÒ‘s P. Evaluation of CD14 in host defense. Eur J Clin Invest. 2000; 30:167-179. https://doi.org/10.1046/j.1365-2362.2000.00610.x PMid:10651843

Hailman E, Lichenstein HS, Wurfel MM, Miller DS, Johnson DA, Kelley M, Busse LA, Zukowski MM, Wright SD. Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. Journal of Experimental Medicine. 1994; 179(1):269-77. https://doi.org/10.1084/jem.179.1.269 PMid:7505800

Bas S, Gauthier BR, Spenato U, Stingelin S, Gabay C. CD14 is an acute-phase protein. The Journal of Immunology. 2004; 172(7):4470-9. https://doi.org/10.4049/jimmunol.172.7.4470 PMid:15034063

Sellati TJ, Bouis DA, Kitchens RL, Darveau RP, Pugin J, Ulevitch RJ, Gangloff SC, Goyert SM, Norgard MV, Radolf JD. Treponema pallidum and Borrelia burgdorferi lipoproteins and synthetic lipopeptides activate monocytic cells via a CD14-dependent pathway distinct from that used by lipopolysaccharide. The journal of Immunology. 1998; 160(11):5455-64.

Fan X, Stelter F, Menzel R, Jack R, Spreitzer I, Hartung T, SchÃ¼tt C. Structures in Bacillus subtilis are recognized by CD14 in a lipopolysaccharide binding protein-dependent reaction. Infection and immunity. 1999; 67(6):2964-8.

Yaegashi Y, Shirakawa K, Sato N, Suzuki Y, Kojika M, Imai S, Takahashi G, Miyata M, Furusako S, Endo S. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. Journal of Infection and Chemotherapy. 2005; 11(5):234-8. https://doi.org/10.1007/s10156-005-0400-4 PMid:16258819

Endo S, Takahashi G, Shozushima T. Et al. Usefulness of Presepsin (Soluble CD14 Subtype) as a Diagnostic Marker for Sepsis. JJAAM. 2012; 23: 27-38. https://doi.org/10.3893/jjaam.23.27

Velkov VV. Presepsin - a new highly effective biomarker of sepsis. Clinical and Laboratory Council. 2012; 2(42):56-62.

Agilli M, Sener I, Yesildal F, Honca T, Aydin I, Akgul EO, Yaman H. A new marker for the diagnosÄ±s of sepsis: presepsin. American Journal of Physiology, Biochemistry and Pharmacology. 2012; 1(1):55-7. https://doi.org/10.5455/jib.20120521073837

Faix JD. Presepsin-the new kid on the sepsis block. Clinical biochemistry. 2014; 47(7-8):503. https://doi.org/10.1016/j.clinbiochem.2014.04.014

Pizzolato E, Ulla M, Galluzzo C, et al. Role of Clinics in the emergency department. Clin Chem Lab Med. 2014.

Zou Q, Wen W, Zhang XC. Presepsin as a novel sepsis biomarker. World journal of emergency medicine. 2014; 5(1):16. https://doi.org/10.5847/wjem.j.issn.1920-8642.2014.01.002 PMid:25215141 PMCid:PMC4129857